@PeterBOstergren

MD, PhD. Associate Professor of Urology, University of Copenhagen. Keen interest in uro-oncology. Views are my own.

Joined May 2016
  • Tweets779
  • Following279
  • Followers705
73Media
Peter Ostergren retweeted
GrupoCentroGU@CentroGu18 Jan 2024
5 abstracts de cáncer de próstata que no te puedes perder en ASCO #GU24
16
1
25
2,127
New evidence supports that circulating levels of serum Insulin-Like Peptide 3 (INSL3) may complement testosterone as a marker for testosterone-producing cells for both clinical and anti-doping purposes. academic.oup.com/jcem/advanc… #antidoping #science #endocrinology #research
6
7
1,148
Today the WHOLE eastern part of Danish Urology gathered on a meeting with focus on #training and #supervision, technical and non-technical skills. What a great initiative that will improve the residency programs in East Denmark. Way to go! @UrologiDK
1
3
18
1,067
1/6 Honoured to be part of these 2 practice changing papers - 15 year RCT outcomes of upfront radical treatment vs monitoring 👉🏾 No difference in cancer or all cause mortality, 95% vs 90% diff in mets free rates nejm.org/doi/full/10.1056/NE… & evidence.nejm.org/doi/full/1…
4
6
29
5,326
Incidence of synchronous M1 PCa is rapidly increasing in 🇩🇰. @ same time PSA @ diagnosis decreasing. Introduction of PSMA-PET? 💪 work from @UrologicalRunit presented by @HeinStroomberg
2
4
14
835
#GU23 @ASCO Much awaited data from the ph3 Propel shows continued rPFS benefits + strong trend for OS (7 month) benefit with abiraterone + olaparib vs. abiraterone in 1st line mCRPC in HRR pos & neg #prostatecancer 👇 @OncoAlert @PCF_Science @MedIQCME #MedIQGU23
5
57
1
122
22,080
A paradigm shift in prostate cancer screening? Grateful to be part of the Göteborg-2 (G2) study group led by Prof. Jonas Hugosson publishing results of this RCT today ⁦@NEJM⁩ @UrologyMSK⁩ ⁦@MSKBiostats⁩ ⁩ ⁦⁦⁦@goteborgsuni⁩ nejm.org/doi/full/10.1056/NE…

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only | NEJM

Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of...

nejm.org
9
37
3
122
Breaking news👉 Ph3 PSMAfore trial with Pluvicto/ lutetium-177 met the primary endpoint of radiographic PFS in PSMA–positive mCRPC #prostatecancer after prior Rx with AR inhibitors but before chemotherapy👇Weblink👉 bit.ly/3FsYaCK @OncoAlert @urotoday
80
9
168
Today, we are looking at the counter argument from @PSUrol et al They argue that the practice of Extended Pelvic Lymph Node dissection during Radical Prostatectomy is unnecessary eu-openscience.europeanurolo… @adityatushar @ReenaDavda
4
19
2
55
Replying to @YankeeAlphaZulu
@YankeeAlphaZulu starting lecture on #pediatricurology with a visual aid to pronounciation of his surname! @MikkelFode @PeterBOstergren @PSKingo @YoungDanishUrol
1
7
What a way to end @CopMich after days w. excellent urological Scientific exchange btw Michigan and Copenhagen. Thx to Professors Dana Ohl and @gpalapa2 for hosting us from 🇩🇰. @HerlevGentofte @UMichUrology @JSnksen @CFuglesangSJ
4
24
A heartfelt and inspiring talk from @NDowJames about the future of Urology and the need for compassion and nontechnical skills, care for the most vulnerable, good quality research with the goal of EBM, worthy and well planned RCTs in all pt groups #Copmich22
1
8
2
37
Peter Ostergren retweeted
Ganesh Palapattu@gpalapa213 Oct 2022
Peter Schlegel opening our CopMich program at the 36th Reed M. Nesbit Society meeting. ⁦@UMichUrology⁩ ⁦@umichmedicine⁩ ⁦@HerlevGentofte⁩ ⁦@WeillCornell⁩
5
34
One clear message from #uromigoslive = no role for testosuppression + docetaxel any longer if have access NHT. Strong and reproducible data of benefit of add abi/daro/enza to TS + concurrent docet @Uromigos @neerajaiims @DrRanaMcKay @Daniel_J_George @Prof_Nick_James @tompowles1
4
57
2
131
A great talk on #screening for #ProstateCancer by @auvinen_anssi during #ECRS. Pinpointing perfectly the pro's and con's of screening. My take-away: we need evidence on risk stratified and mri based screening before implementation. @cancer_dk
4
10
Out now: The Aug/Sept edition of European Urology Today. With reports from EAU22, case studies, updates from the EAU Policy Office and Guidelines office, preview from an upcoming publication about the EAU’s 50th Anniversary and much more! Read it here ▶️ uroweb.org/science-publicati…
7
13
Peter Ostergren retweeted
Toni Choueiri, MD
@DrChoueiri3 Aug 2022
JUST IN: Phase 3 KEYNOTE-921 Trial Evaluating pembrolizumab+docetaxel vs docetaxel alone in Metastatic Castration-Resistant Prostate Cancer (CRPC) did not meet primary endpoints of OS and rPFS @DanaFarber_GU @OncoAlert @Merck @PCFnews merck.com/news/merck-provide…

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to...

merck.com
7
73
10
171
Peter Ostergren retweeted
Alastair Lamb@LambAlastair11 Aug 2022
Delighted to share our new paper in @Nature on “Spatially resolved clonal copy number alterations in benign and malignant tissue”. Collaborative effort from @NDSurgicalSci @UniOfOxford & @SciLifeLab @KTHUniversity & many others. #Organscale nature.com/articles/s41586-0… 1/15
12
46
7
188
Crazy 👏👏👏👏🥳 🇩🇰 Jonas Vingegaard in 🟡 🚴💪🏔 Tour fever continues in Denmark #TourDeFrance2022
Tour de France™
@LeTour13 Jul 2022
🇩🇰 Jonas Vingegaard drops @TamauPogi ! The Yellow Jersey can't follow! 🇩🇰 Jonas Vingegaard décramponne @TamauPogi ! Le maillot jaune vacille ! #TDF2022
4
Peter Ostergren retweeted
Matthias Guckenberger@Mat_Guc9 Jul 2022
Excellent editorial on adjuvant RT for pN+ prostate cancer ascopubs.org/doi/full/10.120… 👉 "ALL pts with pN1 prostate cancer—and particularly those with increasing node positivity—should be counseled on the potential survival benefits of upfront adjuvant RT" ascopubs.org/doi/full/10.120…

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer...

PURPOSEAn association with a reduction in the risk of all-cause mortality (ACM) and the use of adjuvant as compared with early postradical prostatectomy salvage radiation therapy (sRT) in men with...

ascopubs.org
3
40
4
113
Load more